NASDAQ:EYPT Eyepoint Pharmaceuticals (EYPT) Stock Price, News & Analysis $12.93 +0.15 (+1.17%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$12.92 -0.01 (-0.08%) As of 05/22/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eyepoint Pharmaceuticals Stock (NASDAQ:EYPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get EYPT alerts:Sign Up Key Stats Today's Range$12.73▼$13.4350-Day Range$11.70▼$15.0752-Week Range$5.45▼$19.11Volume783,848 shsAverage Volume807,220 shsMarket Capitalization$1.08 billionP/E RatioN/ADividend YieldN/APrice Target$31.80Consensus RatingBuy Company Overview Eyepoint Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States. Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery. Both products leverage sustained-release technology to deliver corticosteroids directly to ocular tissues, aiming to reduce treatment frequency and improve patient compliance compared with traditional eye drop approaches. The company secured FDA approvals for both YUTIQ and DEXYCU in late 2018 and commenced U.S. commercial launches in 2019. Eyepoint is headquartered in New York, with additional facilities supporting manufacturing and clinical development efforts. Since its inception, the company has entered into multiple licensing agreements to expand its product portfolio and explore new ophthalmic indications, while also advancing preclinical programs investigating sustained-release therapies for other retinal and anterior segment disorders. Eyepoint is led by James A. Mazzo, who serves as Chairman, President, and Chief Executive Officer. Under his leadership, the company has built a specialized commercial organization and forged strategic collaborations to broaden its market reach. Eyepoint continues to invest in research and development to enhance its sustained-release platform and pursue additional regulatory milestones that may address unmet needs in ophthalmology.AI Generated. May Contain Errors. Read More Eyepoint Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreEYPT MarketRank™: Eyepoint Pharmaceuticals scored higher than 47% of companies evaluated by MarketBeat, and ranked 550th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingEyepoint Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialEyepoint Pharmaceuticals has a consensus price target of $31.80, representing about 145.9% upside from its current price of $12.93.Amount of Analyst CoverageEyepoint Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eyepoint Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Eyepoint Pharmaceuticals are expected to grow in the coming year, from ($3.16) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyepoint Pharmaceuticals is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyepoint Pharmaceuticals is -3.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyepoint Pharmaceuticals has a P/B Ratio of 4.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eyepoint Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.72% of the float of Eyepoint Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEyepoint Pharmaceuticals has a short interest ratio ("days to cover") of 16.59, which indicates bearish sentiment.Change versus previous monthShort interest in Eyepoint Pharmaceuticals has recently increased by 3.86%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEyepoint Pharmaceuticals does not currently pay a dividend.Dividend GrowthEyepoint Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Eyepoint Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for EYPT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Eyepoint Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eyepoint Pharmaceuticals insiders have sold 85.32% more of their company's stock than they have bought. Specifically, they have bought $19,725.00 in company stock and sold $36,555.00 in company stock.Percentage Held by Insiders4.46% of the stock of Eyepoint Pharmaceuticals is held by insiders.Percentage Held by Institutions99.41% of the stock of Eyepoint Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eyepoint Pharmaceuticals' insider trading history. Receive EYPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyepoint Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EYPT Stock News HeadlinesEyePoint Announces Participation at Upcoming Investor ConferencesMay 19, 2026 | globenewswire.comEyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)A little-known stock pick with money-doubling potential over the next year is revealed for free in the first three minutes of a new video. This company is a critical piece of Elon Musk's fast-growing Starlink technology. It could climb 100 percent or more over the next year as Elon brings Starlink public in what may be the biggest IPO in history. No credit card is required to get the ticker.May 23 at 1:00 AM | Paradigm Press (Ad)Analysts Are Bullish on Top Healthcare Stocks: Trevi Therapeutics (TRVI), EyePoint Pharmaceuticals (EYPT)May 14, 2026 | theglobeandmail.comEyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline DataMay 14, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: EyePoint Pharmaceuticals (EYPT), BeOne Medicines (ONC)May 11, 2026 | theglobeandmail.comEyePoint, Inc. (EYPT) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comIs It Time To Reassess EyePoint (EYPT) After A 120% One Year Share Price SurgeMay 6, 2026 | finance.yahoo.comSee More Headlines EYPT Stock Analysis - Frequently Asked Questions How have EYPT shares performed this year? Eyepoint Pharmaceuticals' stock was trading at $18.27 on January 1st, 2026. Since then, EYPT stock has decreased by 29.2% and is now trading at $12.93. How were Eyepoint Pharmaceuticals' earnings last quarter? Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) released its quarterly earnings results on Wednesday, May, 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by $0.20. The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.35 million. Eyepoint Pharmaceuticals had a negative trailing twelve-month return on equity of 110.54% and a negative net margin of 3,566.63%. Read the conference call transcript. When did Eyepoint Pharmaceuticals' stock split? Shares of Eyepoint Pharmaceuticals reverse split on Wednesday, December 9th 2020.The 1-10 reverse split was announced on Tuesday, December 8th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 9th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Eyepoint Pharmaceuticals' major shareholders? Eyepoint Pharmaceuticals' top institutional investors include Janus Henderson Group PLC (4.30%), Commodore Capital LP (3.37%), Orbimed Advisors LLC (1.28%) and Hsbc Holdings PLC (0.99%). Insiders that own company stock include Ew Healthcare Partners, LP, Jay S Duker, Ye Liu, David Scott Jones, Dario A Paggiarino, Wendy F Dicicco, Michael Craig Pine, David R Guyer and Ramiro Ribeiro. View institutional ownership trends. How do I buy shares of Eyepoint Pharmaceuticals? Shares of EYPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eyepoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eyepoint Pharmaceuticals investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), SPDR Dow Jones Industrial Average ETF Trust (DIA), Advanced Micro Devices (AMD) and Broadcom (AVGO). Company Calendar Last Earnings5/06/2026Today5/23/2026Stifel 2026 Virtual Ophthalmology Forum5/26/2026Jefferies Global Healthcare Conference 20266/03/2026Goldman Sachs 47th Annual Global Healthcare Conference 20266/09/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 EYPT's financial health is in the Green zone, according to TradeSmith. EYPT has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:EYPT CIK1314102 Webeyepointpharma.com Phone(617) 926-5000Fax617-926-5050Employees120Year Founded1987Price Target and Rating Average Price Target for Eyepoint Pharmaceuticals$31.80 High Price Target$37.00 Low Price Target$28.00 Potential Upside/Downside+145.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($3.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$231.96 million Net Margins-3,566.63% Pretax Margin-3,563.62% Return on Equity-110.54% Return on Assets-90.15% Debt Debt-to-Equity RatioN/A Current Ratio6.66 Quick Ratio6.63 Sales & Book Value Annual Sales$31.37 million Price / Sales34.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book4.70Miscellaneous Outstanding Shares83,840,000Free Float80,102,000Market Cap$1.08 billion OptionableOptionable Beta1.76 Social Links 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:EYPT) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
